GCM
ZNTL icon

Graham Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Graham Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Sell
22,358
-70,069
-76% -$280K ﹤0.01% 1141
2026
Q1 		$216K Buy
92,427
+1,517
+2% +$3.92K 0.01% 930
2025
Q4 		$123K Sell
90,910
-61,237
-40% -$89.1K ﹤0.01% 1127
2025
Q3 		$230K Buy
152,147
+116,672
+329% +$175K ﹤0.01% 988
2025
Q2 		$41.2K Sell
35,475
-89,326
-72% -$118K ﹤0.01% 1250
2025
Q1 		$198K Buy
124,801
+66,855
+115% +$144K ﹤0.01% 1138
2024
Q4 		$176K Buy
57,946
+15,760
+37% +$51.6K ﹤0.01% 1099
2024
Q3 		$155K Buy
42,186
+30,721
+268% +$112K ﹤0.01% 967
2024
Q2 		$46.9K Buy
+11,465
New +$128K ﹤0.01% 985
2023
Q4 		– Sell
-10,600
Closed -$213K – 1388
2023
Q3 		$213K Buy
+10,600
New +$269K 0.01% 843

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Graham Capital Management's ZNTL Position: Q2 2026 in Review

Graham Capital Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 76% in Q2 2026, selling an estimated $280K and leaving 22,358 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

Graham Capital Management first reported a position in ZNTL in Q3 2023 and has held it in 10 quarters since. The position peaked at $230K in Q3 2025. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Graham Capital Management held 22,358 shares of Zentalis Pharmaceuticals worth $108K as of Q2 2026.
  • Graham Capital Management sold 70,069 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $280K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1141 holding.
  • Graham Capital Management first reported a position in Zentalis Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Graham Capital Management's Zentalis Pharmaceuticals position peaked at $230K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.